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I have just found 10,000 ways that won’t work.“ 
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II. Zusammenfassung 
 
 
Sklerostin, ein zentraler Regulator der Knochenneubildung, wird nicht nur im 
Knochen sondern auch im Zahnhalteapparat, dem sogenannten Parodont, 
produziert. Sklerostin ist daher möglicherweise an Prozessen beteiligt die den 
Erhalt der Zähne ermöglichen, aber auch pathophysiologische Wirkungen sind 
nicht auszuschließen. Das Ziel dieser Studie war es den Einfluss von 
Signalmolekülen auf die Produktion von Sklerostin bei parodontalen 
Fibroblasten zu untersuchen. 
 
Basierend auf dieser Frage wurden Fibroblasten des parodontalen Gewebes 
mit verschiedenen Signalmolekülen inkubiert. Untersucht wurde die 
Veränderung der Produktion von Sklerostin auf mRNA-Ebene mittels PCR, und 
Proteinebene mittels Westernblot und ELISA. Um eine mögliche autokrine 
Wirkung aufzuzeigen wurden die Fibroblasten mit Sklerostin inkubiert und der 
Einfluss auf Zellfunktionen durch Messungen zur Vitalität, Proliferation, 
Proteinsynthese und Chemotaxis untersucht. 
 
Es konnte gezeigt werden, dass Transforming Growth Factor-beta1 die 
Produktion von Sklerostin auf mRNA- und Proteinebene steigert. Die Erhöhung 
erfolgte zeit- und dosisabhängig. Rekombinantes Sklerostin zeigte hingegen 
keinen Einfluss auf die Zellfunktionen Vitalität, Proliferation, Proteinsynthese 
und Chemotaxis parodontaler Fibroblasten. 
 
Die Produktion von Sklerostin in parodontalen Fibroblasten unterliegt demnach 
einer Regulation durch Transforming Growth Factor-beta1. Dass die Regulation 
von Sklerostin einem autokrinen Mechanismus unterliegt konnte nicht bestätigt 
werden. Die funktionelle Bedeutung der Regulation von Sklerostin im Parodont 
ist noch unklar. 
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III. Abstract 
 
 
Sclerostin, a key regulator of bone regeneration, is not only expressed in bone 
but also in the tooth supporting apparatus, the periodontium. Thus, sclerostin 
may be involved in teeth-preserving processes, but pathophysiological effects 
cannot be ruled out. The aim of this study was to reveal effects of signaling 
molecules on the expression of sclerostin in periodontal fibroblasts. 
 
The effect of different signaling molecules was tested on periodontal fibroblasts. 
Changes in the expression of sclerostin were determined on mRNA level with 
PCR and on protein level with Western Blot and ELISA. To show a possible 
autokrine regulatory mechanism, the fibroblasts were incubated with sclerostin 
and the impact on cell functions viability, proliferation, protein synthesis, and 
chemotaxis was studied. 
 
It was found that transforming growth factor-beta1 increased sclerostin on 
mRNA and protein level. This increase was time-dependent and dose-
dependent. Recombinant sclerostin, however, showed no effect on cell viability, 
proliferation, protein synthesis, and chemotaxis. 
 
These findings show that in periodontal fibroblasts sclerostin is regulated by 
transforming growth factor-beta1. That sclerostin is regulated through an 
autokrine mechanism could not be confirmed. The functional role of the 
regulation of sclerostin in the periodontium is still unknown. 
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IV. List of Abbreviations 
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DMSO dimethyl sulfoxide 
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OB osteoblast 
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OC osteocyte 
OE oral epithelium 
OD optical density 
OD-medium osteoblast differentiation medium 
PBS phosphate-buffered saline 
PCR polymerase chain reaction  
PDGF platelet-derived growth factor (synonymous for PDGF-BB) 
PDL periodontal ligament 
PDLF periodontal ligament fibroblasts 
PDLF 1/2/3 periodontal ligament fibroblasts from donor 1/2/3 
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1 Introduction 
The first part of the following chapter shall give an introduction of the 
anatomical, histological and physiological make-up of the tooth. Then take a 
closer look at the periodontium; its structures, functions, tissues, and 
development. In the second part sclerostin, a key regulator of bone formation, is 
described – structure, function, and history. Then the present scientific 
knowledge of sclerostin follows with the reasoning and need for this diploma 
thesis along with the study’s objectives. 
 
1.1 The Tooth 
The teeth play an important role in the nourishment; they are one of the first 
steps of digestion. (1-3) Through mastication food is crushed and mixed with 
saliva to a mash before it is further digested. (4, 5) But the teeth have other 
functions as well. They are important for a clear articulation, as a tool or as a 
weapon for defense in phylogenic development (3) and in modern times 
aesthetic plays an important role in social attractiveness. (6) 
 
 
Figure 1: Permanent dentition set. The different forms and occlusal surfaces are shown. There are 
four different types of teeth in human dentition incisors, canines, molars and premolars. (7) 
 
Human teeth are heterodontic – the dentition is made up of different specialized 
set of teeth, and dyphodontic - two complete set of teeth. The primary dentition, 
with 20 deciduous teeth, is replaced by the secondary dentition, with 32 
permanent teeth. (3, 8) The form of the teeth differs depending on their function. 
Incisors and canines have a slimmer figure with a cuspid formed occlusal 
surface for cutting. Molars and premolars are stockier, broader in form and have 
a wider blunt occlusal surface for grinding. (2, 3, 8)   
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1.1.1 Anatomy 
 
Figure 2: Tooth in cross-section. The tooth can be 
divided into three layers - crown, neck, and root. On top 
dentine is coated by enamel, the lower part by 
cementum. Underneath the dentine is the pulp with its 
apical root canal that leads blood and nerve vessels 
into the bone. The PDL anchors the tooth via cementum 
to the alveolar bone. The gingiva encloses and fixates 
the tooth at the neck level. (9)  
 
 
 
 
Figure 2 shows the different layers of the tooth in cross section: functional 
structures and surrounding tissues. The tooth can be structured into three main 
parts: crown, neck and root. The crown is the upper visible part of the tooth 
above the gingiva. The root is the lower part that lies in the alveolar bone. The 
neck lies between crown and root at the point of attachment of the gingiva. 
 
The crown is coated with enamel, underneath is dentine. At the crown dentine is 
covered by enamel and at the root by cementum. Under the dentine is the pulp 
cavity containing the pulp. Apical the pulp goes over into the root canal that 
leads blood vessels and nerves into the surrounding bone tissue. The PDL 
connects with the cementum on the tooth and anchors it within the alveolar 
bone of the maxilla or mandible at the root. The gingiva encloses and fixates the 
tooth at the neck level and seals the periodontal gap off to the oral cavern. (1-3) 
 
Anatomically enamel, dentine, pulp and cementum are structures of the tooth. 
PDL, gingiva and alveolar bone form the periodontium, the so-called tooth-
holding apparatus. Although anatomically cementum is put with the tooth it 
functionally belongs to the periodontium. (3) 
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1.1.2 Histology 
Enamel coats the tooth from crown to neck. It is the hardest tissue in the human 
body and consists to 97% of minerals in form of hydroxyapatite. (1, 3) The 
enamel is produced by ameloblasts during tooth development. (1) The hard 
tissue is unable to regenerate; it declines with age due to attrition and abrasion. 
(1, 2) 
 
Dentine encloses the pulp cavity. It is highly mineralized, up to 70% inorganic 
components, and has a composition similar to bone only harder. (1-3) The main 
organic components are collagen fibers, type I, and different matrix proteins. (1, 
3) Dentine producing odontoblasts are lined near the pulp cavity. (1, 2) They 
produce dentine during teeth development and keep this function postnatal. (1) 
 
Cementum covers the dentine from neck to root. (1-3) It is a hard tissue, 
consisting to 65% of minerals, hydroxyapatite; organic components are collagen 
fibers type I and cells. (1, 3) Cementum has a low turnover rate, but is produced 
by cementoblasts lifelong. Cementoblasts form a thin layer on the outside of the 
cementum, can differentiate to cementocytes, and connect to the PDL. (1, 10) 
 
Pulp – a loose fine-fibrous connective tissue - is contained within the pulp 
cavity. (1-3) The pulp consists of a glycosaminoglycans-rich matrix with 
imbedded fibers – collagen type I/III and elastic fibers. (1) There are three main 
types of cells into the pulp: odontoblasts, fibroblasts and free-moving cells. The 
odontoblasts lie on the pulp-dentine-border, are responsible for the production 
of dentine and impulse conduction. The fibroblasts can differentiate to 
osteoblasts as well as regulate the turnover of the matrix and stem cells. Free-
moving cells are mainly lymphocytes, macrophages or dendritic cells for 
immunological functions. Nerve and blood vessels are connected to 
surrounding tissue through the root canal and nourish the tissue. (1, 3)   
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1.2 The Periodontium 
The periodontium consists of soft tissues – gingiva, PDL - and hard tissues – 
cementum, alveolare bone. The structures are responsible for different 
functions. (10) For example: anchoring the tooth in the alveole, as immune 
defense due to the lymphatic cells and sensoric functions - pain, pressure, and 
tactile sensitivity (1-3, 10) - as well as a nutritive function. (11, 12) Further the 
periodontium has a high physiological and functional remodeling rate which 
enables it to regenerate defects caused by mechanical occlusal pressure, 
human anterior tooth movement, aging or dental treatment. (1-3, 10) The 
periodontium absorbs the pressure put on the tooth, converts it into traction and 
moves the tooth back into its original position. The traction stimulates bone 
formation in the alveolar bone. (13) If the periodontium is damaged, the 
pressure on the bone causes bone resorption; as is observed after tooth loss. 
(8) 
 
1.2.1 Anatomy and histology 
The Periodontium consists of four parts - cementum, PDL, gingiva, and alveolar 
bone - that form a functional unit. (1-3, 10) 
 
 
Figure 3: Periodontium. Cementum, PDL, alveolar bone, and gingiva form a functional unit that 
anchors the tooth in the aleveole. (14) 
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1.2.1.1 Cementum 
Cementum has already been partly discussed in the former chapter. The 
cementum covers the root dentine, tightly interconnected, and is thickest at the 
apical end of the root. It consists of mineralized matrix, cells and collagen fibers. 
For the periodontium the cementum is important for the attachment to the PDL 
and the anchoring of the tooth to the alveole. (1-3) The make-up of the matrix is 
similar to that of bone. There are two different collagen fiber nets; fine intrinsic 
fibers, Ebner fibrils, that spiral around the root and extrinsic fibers, Sharpey 
fibers, radially running periodontal fibers. The extrinsic fibers are most common 
on the outside and middle of the cementum. (3) Further there are four different 
types of cementum depending of the composition of cells, cementocytes, and 
fibers. (1, 3, 10) 
 
 
Figure 4: Cementum. The cementum (C) lies between dentine (D) and PDL. It consists of 
cementoblasts (CB) lined on the PDL-near surface and built-in cementocytes (CC). (15) 
 
1.2.1.2 Gingiva 
The gingiva is a specialized type of the oral mucosa with a high turnover and 
regeneration rate. It consists of collagen connective tissue – collagen type I/III – 
blood vessels, nerves, lymph, as well as fibroblasts, fibrocytes and free moving 
cells. (1, 3) The gingiva surrounds the tooth at the neck and closes the 
periodontium at the coronal end off. (1-3, 8) It stabilizes the tooth supporting the 
anchoring within the alveole. (1-3) It is distinguished between three epitheliums. 
(i) oral epithelium is interconnected with the connective tissue and lines the 
outer part of the gingiva facing the oral cavern. (ii) junctional epithelium 
surrounds the neck of the tooth. It is unkeratinized, undifferentiated, and not 
interconnected with the connective tissue. (iii) sulcular epithelium lies between 
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oral and junctional epithelium. Subepithelial lies connective tissue consisting of 
collagen fibers with fibrocytes and free cells; blood vessels and nerves are also 
present. Also a supraalveolare fiber apparatus that consists of fiber bundles 
which insert in the root surface. The fiber apparatus surrounds the root, 
connects the gingival tissue with the tooth neck and the alveolar ridge. (1, 3, 10)  
 
 
Figure 5: Gingiva. The gingival structure consists of subepithelial connective tissue (CT) covered 
by oral epithelium (OE), and junctional epithelium (JE) by the enamel space (ES). Sulcular 
epithelium (SE) is oral epithelium at the gingival sulcus. (16) 
 
1.2.1.3 PDL 
The PDL is a fibrous attachment apparatus that anchors the tooth at root level 
to the alveolar bone. (1, 10) It lies in a gap of 0.1 – 0.2 mm, periodontal gap, 
between tooth and alveolar bone (1) and functions as a syndesmosis. (3) The 
PDL consists of firm collagen and elastic fibers that run from crown to root and 
Sharpey fibers inserting and spanning between cementum and alveolar bone. 
(1, 3, 10) The ligamentous apparatus absorbs the pressure put in the tooth 
caused by mechanical loading. Cells, nerve, blood, and lymph vessels are also 
present in the PDL. The blood vessels help to distribute the occlusal pressure 
hydrodynamically. (1, 3) The cells, mainly fibroblasts, are responsible for the 
regeneration of the periodontium. They produce new collagen fibers and can 
differentiate to cementoblasts and osteoblasts. (1, 3) 
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Figure 6: PDL. The attachment of the PDL to the alveolar bone (AB) and the root - cementum (C) 
connected to dentin (D) - via collagen fiber bundles is shown. (17)  
 
1.2.1.4 Alveolar bone 
In the alveole the bone is made of compact bone tissue with small perforations, 
Volkmann canals, for nerve, lymph, and blood vessels. Adjacent is spongy bone 
tissue that undergoes steady remodeling. (1, 3) For example due to the 
tendency of the anterior movement of human teeth the mesial alveole wall 
undergoes resorption and the lateral wall bone formation. (1) The PDL-near-
surface of the alveole is interlaced with Sharpey fibers from the PDL. This 
guarantees a tight connection of the PDL to the bone. (1, 10) 
 
 
Figure 7: Alveolar bone. The outer side of the alveolar bone is made of compact bone, followed on 
the inside by spongy bone containing Volkmann canals for nerve, lymph, and blood vessels. 
(18) 
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1.2.2 Cells – origin, differentiation and function 
 
1.2.2.1 GF 
The gingiva is of mesodermal (19) and ectodermal (10) origin. Due to 
heterogeneity of the fibroblasts they derive from different sources, e.g. 
perifollicular mesenchyme or undifferentiated perivascular cells. The GF are 
involved in stabilizing the tooth and keep it from rotation. (11) The turn-over rate 
of the gingiva is lower than in PDL, but higher than in bone or skin. (10)  
 
 
Figure 8: Oral fibroblasts. The cells were taken from incisive vestibules of a rabbit. (20) 
 
1.2.2.2 PDLF 
In the PDL the most common type of cells are PDLF. (11) They are of 
ectomesenchymal origin. (10, 19) Periodontal fibroblasts derive from precursor 
cells of the dental follicle. (10) Different subpopulations of fibroblasts are known. 
One of them are osteoblast-like fibroblasts that are able to differentiate to 
cementoblasts and osteoblasts. (11) In the PDL undifferentiated stem cells 
remain with the potential to turn into fibroblasts, cementoblasts and osteoblasts. 
(11) PDLF are needed for production of components of the extracellular matrix 
(11) and are responsible for the remodeling of the tissue. (1) The turnover of the 
PDL is higher than that of gingiva and skin. (10) 
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Figure 9: PDLF. Fibroblasts of the PDL (PDLF) can differentiate into cementoblasts (CB) and 
osteoblasts (OB). Cementoblasts lie near the cementum (C) and osteoblasts near the alveolar bone 
(AB). (15) 
 
1.2.2.3 Cementoblasts 
Cementoblasts origin from ectomesenchymal cells. (10) Precursor cells from the 
dental follicle are able to differentiate to cementoblasts. (10, 12) The cells form 
a thin layer on the outside of the cementum. (1) Mature cementoblasts are built 
into mineralizing cementum matrix and become cementocytes. (1, 3) 
Cementocytes lie in lacunae, like osteocytes, and are connected with cell 
extensions via canaliculi. (1, 3)  Also cementoblasts and cementocytes 
participate in the production of intrinsic fibers. Extrinsic fibers, Sharpey fibers, 
are secreted by PDLF. (1) 
 
 
Figure 10: Cementoblast and cementocyte. (A) Lying on the PDL-cementum (C) border is a 
cementoblast (CB) with cytoplasmatic processes (CP). (21) (B) A cementocyte (CC) lying in a 
lacunae (L) with surrounding lacuna wall (LW) in cellular mixed fiber cementum (CMCF). (22)  
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1.2.2.4 Osteoblasts 
The alveolar bone is of ectomesenchymale origin. Osteoblasts derive from 
periodontal progenitor cells of the dental follicle and are able to further 
differentiate to osteocytes. (10, 12) Osteoblasts build new bone through 
imbedding osteoblast into new mineralizing bone matrix. (10, 23) The built in 
osteoblasts differentiate into osteocytes, lie in lacunae and are connected via 
cell extensions. (10) Further there are osteoclasts in the bone. They are 
multinuclear giant cells lying in Howship’s lacunae on the bone surface. 
Osteoclasts evolve from fusioning of hematopoietic mononuclear marrow 
progenitor cells and are responsible for the resorption of bone. (10, 23) 
 
 
Figure 11: Osteoblasts. Osteoblasts (OB) lie on the border of a bone forming layer, 
osteoid layer (O). Inside the alveolar bone is a built-in osteocyte (OC). (24) 
 
 
GF and PDLF are established models for in vitro studies (25) and were used in 
this research project. 
 
 
Figure 12: GF and PDLF in vitro. (magnification x10) 
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1.2.3 Regulation and regeneration 
The periodontal tissues are continually regenerated to repair damages; e.g. 
caused by mechanical loading due to mastication, but also local inflammation. 
Therefore the cells have to be able to react to local signaling molecules, which 
are released upon damage of the tissue. (10) Under physiological conditions a 
cellular control mechanism regulates the remodeling of the periodontium and 
subsequently the anchoring of the tooth in the alveolar bone. Under pathological 
conditions the repair mechanisms can be disrupted or overstressed and the 
resorption can take overhand. (26) 
 
 
Figure 13: (A) In periodontitis inflammation causes loss of soft tissue and alveolar bone. (B) 
Periodontal repair is characterized by formation of a long junctional epithelium. (C) In regeneration 
the functional structures of the periodontium are fully restored. (17) 
 
One of the most common chronic inflammatory diseases in adults is 
periodontitis. (10) Periodontitis is caused by bacteria that accumulate at the 
gingival sulcus, forming plaques, and cause inflammation within the 
periodontium. (10) Without treatment it comes to destruction of soft tissue in the 
periodontium and to bone resorption. (10, 17) The resorption leads to the loss of 
attachment and subsequently to the loosening and loss of the tooth. (10, 17) 
Periodontitis is therefore a serious clinical problem that affects large parts of the 
adult population. (10, 26) 
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For the treatment of attachment loss two strategies of healing can be followed: 
periodontal repair and regeneration. In repair, the aim is to heal the defect, but 
without restoration of the involved tissues. Characteristically for repair is the 
formation of a long junctional epithelium. On the other side, the aim of 
regeneration is to fully restore the functional structures of the periodontium – 
gingiva, cementum, PDL and alveolar bone. Another goal is to ensure the 
attachment between root and connective fibers as well as between tooth and 
junctional epithelium. (Figure 13) (17) 
 
Bosshardt and Sculean presented an overview of recent studies in the field of 
regenerative techniques – the different methods and their potential. (17) 
Conditioning of the root surface could be of clinical interest for enhancing the 
attachment and expanding of cells onto the surface. Bone grafts and bone 
substitute materials, depending on the type used, can support new bone 
formation. In combination with barrier membranes in guided tissue regeneration 
their regenerative effect is known. Also of interest are enamel matrix proteins. 
Studies gave evidence that these proteins assist in the production of new 
periodontal structures and wound healing. Of clinical interest the enamel matrix 
protein Emdogain® which showed positive impact in the treatment of 
periodontitis in clinical studies. (17) Although growth and differentiation factors- 
like IGF, FGF, PDGF, PTH, TGF-β, and BMPs showed high potential in 
preclinical studies, they are still not yet uses as standard therapeutics. (14, 17) 
 
All in all regeneration of the periodontal structures is possible. Although with the 
present available methods only partial reconstruction of the functional tissues is 
achieved. (17) Consequently, there is a high demand for further studies. 
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1.2.4 Growth factors in the periodontium 
As mentioned in the previous chapter, TGF-β1 and PDGF-BB are growth 
factors used in periodontal regeneration, clinically as well as in studies, and 
show a lot of potential. 
 
1.2.4.1 TGF-β1 
TGF-β1 is a cytokine belonging to the highly conserved TGF-β family and is one 
of three forms - β1, β2, β3. The growth factor is a dimeric polypeptide consisting 
of a disulfide bond connecting two amino acid chains. (30, 31) TGF-β1 binds to 
the corresponding receptors TGFβ- type I and II, which can be found in many 
cells.  TGF-β1 is involved in regulatory functions of cells like adhesion, 
migration, differentiation, proliferation, (31) and immune regulation. (30) It has 
dual functions, for example it can inhibit or stimulate proliferation in the same or 
different cells types. (30) Also it regulatory effects different growth factors and 
causes stimulation in mesenschymal cells. (31) TGF-β1 is present in tissues of 
the PDL and may be important for the preservation of PDL structures. Also 
TGF-β1 may promote differentiation of progenitor cells to fibroblasts. (32) 
Further it may regulate fibroblast differentiation via periostin, through FAK-
dependent pathways. (33) In tooth morphogenesis signaling of TGFβ-1 via type 
II receptors play a major role in the formation of dentine and maturing of 
odontoblasts. (34) TGF-β1 can modulate the eruption of teeth in adolescent 
rats. The growth factor was found in osteoblasts, PDLF and cementoblasts in 
the periodontium. (35) 
 
1.2.4.2 PDGF-BB 
PDGF-BB is a homodimer with an eight cysteine motif and is mitogenic for 
mesenchymal cells, like osteoblasts or their progenitor cells. (27, 28) In PDLF it 
positively effects proliferation and chemotaxis. (29, 30) PDGF-BB was one of 
the first growth factors clinically used – mostly combined with guided tissue 
regeneration. The FDA approved rhPDGF-BB, in therapeutical use for 
regeneration of periodontal defects, as secure and successful. (29) 
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1.3 Sclerostin – a key regulator of bone remodeling 
 
1.3.1 Sclerosteosis and Van Buchem 
In 2001 different mutations in a new gene, SOST (MIM 605740), were identified. 
A nonsense mutation in the SOST gene is responsible for sclerosteosis (MIM 
269500). Causes are problems with the splicing or a premature break off of the 
encoding due to an early stop codon. (36, 37) A 52-kb deletion in the enhancer 
region downstream of SOST causes the disease Van Buchem (MIM 239100), 
also called hyperostosis corticalis generalisata. (37-39) Sclerosteosis and Van 
Buchem are sclerosing bone dysplasias, with a characterizing hyperostosis. 
(40, 41) Both mutations are autosomal recessive; meaning only in homozygous 
form a phenotypic manifestation developes. (41) Sclerosteosis is the extremer 
form of the two; clinical manifestations are more severe than in patients with 
Van Buchem - milder form. (42, 43) 
 
 
Figure 14: Clinical manifestations of sclerosteosis and Van Buchem. (A) The characteristical 
broadening of the jaw and deformation of facial structures in sclerosteosis. (41) (B+C) X-rays of 
patients with Van Buchem – (A) child and (B) adult – with increased bone mass in the adult. (44)  
 
The pathological bone overgrowth leads to clinical symptoms that are rather 
prominent at the mandible and the skull. Typical manifestations are the 
enlargement of the facial bones and the jaw that lead to distortion of facial 
structures. The thickening bones can compress nerves and lead to facial palsy 
as well as loss of sight, smell, and hearing. (43) Also the thickening of the scull 
A B C
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can cause an increase of intracranial pressure, which can be lethal. (41-43) 
Further syndaktyly and a tall stature have been reported. Clinical manifestations 
can also be found in the dental region. (42) Position and shape of teeth can be 
anormal, malocclusion, belated eruption of teeth as well as partial anodontia 
have been observed. (41, 45) Often the extraction of teeth are rather difficult. 
(45) This observations led to the conclusion that the protein of the SOST gene, 
sclerostin (MIM 605740), must play a role in the control of bone formation. (37)  
 
1.3.2 Sclerostin 
Sclerostin is encoded by the SOST gene in humans. SOST lies at the locus 
17q12-q21. (37-39) The gene consists of two exons and one intron with a total 
size of 5 kb. Sclerostin is a secreted glycoproteine that belongs to the 
Cerberus/DAN-family, a family of BMP antagonists characterized by a C-
terminal cysteine knot-like domain. (46) The sclerostin protein consists of 213 
amino acids. (47) 
 
 
Figure 15: Locus of the SOST gene in humans. The gene lies at 17q12-q21, consists of two exons 
and one intron, and has a size of 5 kb. (40)  
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Figure 16: Amino acid sequence of sclerostin in humans. The secreted glycoprotein consists of 
213 amino acids. (47) 
 
Sclerostin is expressed during fetal development as well as SOST mRNA in a 
few tissues postnatal and in adults (36, 37, 48, 49). Several studies tested for 
expression of SOST mRNA and sclerostin protein in different human and 
murine tissues. (36, 37, 49) SOST mRNA was found in different human tissues 
– colon, skin, placenta, aorta, heart etc. – with highest expression in kidney, 
liver, cartilage, and bone - but no detection of protein. (36, 37, 50) (Figure 17) 
However, in mineralizing matrix imbedded cells can postnatally express 
sclerostin, for example osteocytes, cementocytes, and chondrocytes, when 
hypertrophic and terminally differentiated. (41, 51-54) 
 
 
Figure 17: SOST mRNA expression in human tissues. Highest expression of SOST mRNA was 
found in bone, cartilage, kidney, and liver. Copies/µl are shown as raw mean SOST values (open 
bars), normalized to PPI (solid bars), and normalized to DAD1 (gray bars). (37) 
  
1 mqlplalclv cllvhtafrv vegqgwqafk ndateiipel geypepppel ennktmnrae 
61  nggrpphhpf etkdvseysc relhftryvt dgpcrsakpv telvcsgqcg parllpnaig 
121  rgkwwrpsgp dfrcipdryr aqrvqllcpg geaprarkvr lvasckckrl trfhnqselk 
181  dfgteaarpq kgrkprprar sakanqaele nay 
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1.3.3 Wnt-signaling path way 
Sclerostin is secreted by osteocytes and transported to the bone surface via 
canaliculi to the circumferenting osteoblasts. (51) Sclerostin hinders 
osteoblastogenesis and promotes apoptosis of osteoblasts. Therefore the 
formation of new bone is lowered. (55) Wnt signalling can be influenced through 
different means; e.g reduction of sclerostin expression via mechanical loading. 
(56) 
 
In canonical Wnt signaling, Wnt forms a complex through binding to LRP 5/6 
and frizzled, a transmembrane receptor. GSK3β is inhibited, β-catenin 
accumulates and migrates into the nucleus where it activates TCF/LCF. 
Subsequently transcription of target genes starts. Sclerostin – also Dkk and Sfrp 
- inhibit the differentiation of osteoblasts through blocking of the Wnt-signaling 
pathway. The protein binds the receptors LRP 5/6 so Wnt cannot bind and no 
complex is formed. A degradation of ß-catenin follows through phosphorylation 
and proteolysis by GSK3β. TCF/LEF are not activated and transcription of a 
target gene is not possible. (57, 58) 
 
 
Figure 18: Wnt-signaling pathway. (a) SOST, Dkk and Sfrp are inhibitors that block binding of Wnt 
to LRP 5/6 and Frizzled. Without Wnt GSK3β causes degradation of β-catenin. (b) If Wnt is present 
β-catenin migrates into the nucleus, activates TCF/LEF and target gene transcription starts. (57)  
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Recently LRP 4 has been described to bind sclerostin and Dkk in vitro. Choi et 
al. concluded that the receptor is involved in the growth and turnover of bone. 
(59) Further results suggest that sclerostin and Dkk regulate LRP 5 induced 
Wnt signaling independently. (60) 
 
 
1.3.4 Current studies of sclerostin 
The physiological importance of sclerostin is observed in experiments with 
genetically modified mice. These observations lead to the conclusion that 
sclerostin inhibits the formation of new bone. (58, 61, 62) For example a 
sclerostin knock-out mouse has pathologically increased bone formation. (61, 
63) 
 
1.3.4.1 α-hSOST 
The increase of new bone formation is of therapeutical interest for treatment 
with sclerostin neutralizing antibodies. In the future, this could be a possible 
medication for the treatment of osteoporosis as well as for the enhancement of 
bone regeneration, e.g. after fractures. (64, 65) Several studies showed the 
potential of αSOST in animal models – mouse, rat and monkeys. (61, 64-69) 
 
As mentioned before, physiological manifestations that are observed in SOST(-/-) 
knock-out mice are increase in BMD, bone mass, formation, and strength. (61, 
65) Studies for fracture healing - closed fracture of the femur - in rats showed 
that αSOST promotes at the fracture site strength and mass of bone. Further 
trabecular and cortical bone of healthy bones had enhanced strength, formation 
and mass. (68) The same results were observed by neutralization of sclerostin 
with αSOST in healthy male rats. (67) Another study demonstrated the increase 
in bone formation with αSOST through screws implanted at metaphyseal sites. 
A 50% increase of the pull-out force, in comparison to a control, was achieved. 
(66) 
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Ominsky et al. investigated the effect of αSOST on fracture healing in male 
cynomolgus monkeys with a fibular osteotomy. (68) The effect of humanized 
αSOST was studied in females cynomolgus monkeys with intact gonads. (69) In 
the male osteotomy model the fracture gap was thinner compared to controls 
and in both models bone strength, formation, and mass was increased. (68, 69) 
 
In 2011 Padhi et al. - for Amgen® - published data of the first clinical phase I 
study with a monoclonal antibody for sclerostin, AMG 758, in humans. It was 
reported that the antibody, used in single dose, showed rise in markers for bone 
formation and BMD, as well as a dose-related decline in markers of bone 
resorption. The study medication was classified as generally safe and well 
tolerated. (70) The results encouraged further studies on this sclerostin 
neutralizing antibody and are now in phase II of clinical studies. (71) 
 
 
Figure 19: SOST
(-/-)
 mouse in comparison to a normal wild-type (WT). The knock-out (KO) mouse 
shows a higher BMD than the wild-type. (61) 
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1.3.4.2 Regulatory factors 
The regulation of the expression of sclerostin is the aim of active research. At 
present it could be shown that functional loading (63, 72) but also oxygen 
tension are involved in the regulation of sclerostin expression. (73) Analysis of 
the effect of hormones, like PTH are also available. Although these studies are 
mostly limited to bone cells, especially osteocytes. (74-77) 
 
1.3.4.3 Sclerostin in dentistry 
In recent studies the expression of sclerostin in the periodontium has been 
observed. Sclerostin is expressed by cementocytes and therefore expressed in 
the periodontium. (52, 78) Also fibroblasts, isolated from the periodontium, 
express sclerostin as well as odontoblasts. (78, 79) These observations are not 
really surprising since cementocytes and also osteocytes – later are the main 
producers of sclerostin (51-54, 58, 62) – are imbedded in a mineralized matrix. 
(52, 78) Sclerostin, and also the Wnt-signaling pathway, are involved in the 
control of embryonic development of the tooth and its surrounding tissues. (48, 
79) The Wnt-signaling pathway is not only active in embryonic periodontal 
development but also in PDLF of adult mice. (80) 
 
 
Figure 20: Expression of sclerostin by cementocytes (triangle) in a wisdom tooth (3
rd
 molar) (52) 
 
 
Figure 21: Expression of sclerostin by osteocytes (triangle) in cortical bone. (52)  
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At present there are no clinical studies concerning sclerostin as a possible 
target for dental treatment – in inflammation or dental defects. As mentioned 
before clinical studies with sclerostin neutralizing antibodies are showing 
promising results. Yet, these studies concentrate on the postcranial skeleton, so 
an impact on the periodontium may be possible and cannot be ruled out. Of 
interest for clinical use of such antibodies in dentistry could be healing of 
implants into the alveolar bone or minimalizing the risk of tooth loosening and 
loss in risk groups, e.g. patients with osteoporosis. (65, 81) 
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1.4 Problem 
At present there are no studies about the regulation of sclerostin in the 
periodontium. These studies are of importance to understand the cellular 
processes of periodontal regeneration as well as pathological changes. 
Theoretically, a deficiency of sclerostin leads to a hypercementosis and thus to 
a narrowing of the periodontal gap. The constriction of the gap can lead to an 
ankylose, a boney anchoring of the tooth within the bone without PDL. This 
could maybe explain the difficulties of tooth extraction by people with 
sclerosteosis. (45) 
In contrast, the overproduction of sclerostin may lead to the loss of mineralized 
periodontal structures – cementum and alveolar bone. So the regulation of the 
expression of sclerostin in the periodontium may have a physiological function, 
and a pathological role can also not be ruled out. Therefore it is important to 
identify the factors - expressed in the periodontium – that are involved in the 
regulation of sclerostin expression. 
 
1.5 Aim 
Investigations on how sclerostin is regulated in the periodontium may shed light 
on the role of sclerostin in the periodontium. Therefore, the aim of this study 
was to reveal effects of signaling molecules on the expression of sclerostin in 
periodontal fibroblasts. 
 
1.6 Research questions 
1. Do signaling molecules have an effect on the expression of sclerostin in 
periodontal fibroblasts? 
2. Does sclerostin effect cell functions through an autokrine mechanism? 
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Media 
 Serum-containing (SC-medium): α-MEM (PAA E15-832), 10% fetal calf 
serum (FCS; PAA 15-151) and 1% antibiotics (P/S/A; PAA). 
 Serum-free medium (SF-medium): α-MEM and 1% antibiotics (P/S). 
 Osteoblast differentiation medium (OD-medium): α-MEM, 20% FCS, 1% 
P/S/A, 10mM glycerophosphate (GP), 10-7M dexamethasone (DEXA) and 
50µM ascorbic acid-di-phosphate (AA-2-P) 
 
2.1.2 Signaling molecules 
 h platelet released supernatant (hPRS) (82) 
 rh basic fibroblast growth factor (rhbFGF; R&D Systems 233-FB) 
 rh bone morphogenic protein-6 (rhBMP-6; R&D Systems 507-BP) 
 L-mimosine (L-Mimo; Sigma-Aldrich M0253) 
 rh parathormone (rhPTH; Bachem 1026840) 
 rh platelet-derived growth factor (rhPDGF-BB; R&D Systems 220-BB) 
 rh SOST/sclerostin (rhsclerostin; R&D Systems 1406-ST-025) 
 rh transforming growth factor beta-1 (rhTGF-β1; R&D Systems 240-B-002) 
 
2.1.3 Antibodies 
 Anti-human goat monoclonal SOST (α-hSOST; R&D Systems 1406-AF) 
 Anti-human goat polyclonal β-actin (α-hβActin; Santa Cruz I-19 sc-1616-R) 
 Polyclonal goat anti-rabbit Ig with HRP (α-rabbit HRP Dako P0448) 
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2.1.4 Viability, proliferation and protein synthesis assay 
 3[H]leucine (Hartmann Analytic MT 672E; Leucine, L-[4,5-H3]) 
 3[H]thymidine (Hartmann Analytic MT 6035; Thymidine, [mezhyl-3H]-) 
 Dimethyl sulfoxide (DMSO; Merck 1.02952.1000)  
 Scintillate cocktail (NEN Perkin Elmer 601 3611 Microscint 0) 
 Top Seal A 96 well (NEN/Perkin Elmer 6005185) 
 
2.1.5 Western Blot 
 Acrylamid bis solution 40% (AA-bis; Merck/VWR 1.00640.1000) 
 Blotting paper (Amersham HyphonTM) 
 LandMarkTM Broad-Range Protein marker (Mbiotech MBI-20050) 
 Microscopy Hemacolor® staining kit (Merck 1-11674.0001) 
 Nitrocellulose membrane (VWR GHERPN203D) 
 Western Blotting Detection System (AmershamTM RPN 2132) 
 X-ray film (Amersham 28102) 
 
2.1.6 ELISA 
 Sclerostin ELISA-kit (Biomedica 100503; BI-20492 Sclerostin) 
 
2.1.7 PCR 
 DNAse I Amplification Grade (Invitrogen 18068-015) 
 Loading Dye (Fermentas #R0611) 
 MassRulerTM DNA Ladder, Low Range (Fermentas #SM0383) 
 Micro Amp Fast 96-well reaction plate 0,1 ml (Applied Biosystems 4346907) 
 Primer pairs (GenXpress) 
SOST 
 f   5’-ccacccctttgagaccaaagacgt-3’ 
 r   5’-ggcccatcggtcacgtagcg3’ 
β-actin (83) 
 f   5’-gcatcccccaaagttcacaa-3’ 
 r   5’-aggactgggccattctcctt3’ 
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 RNeasy Mini Kit (Qiagen 74104) 
 Sealing (IBL) 
 Super ScriptTMIII Platinum® SYBR® Green one step qRT-PCR Kit with ROX 
(Invitrogen/Fisher Scientific 11746-100) 
 Water – molecular biology grade (AppliChem 7732-18-5) 
 
2.1.8 Equipment 
 Beta counter (Packard Top Count NXTTM) 
 Boyden Chamber (NeuroProbe #5956) 
 Photometer (Molecular Devices SPECTRAmax® PLUS384) 
 Radioactive cassette (Amersham Hypercassette) 
 Western Blot apparature (Bio-Rad Mini Protean® Tetra Cell) 
 PCR-machine (Applied Biosystems, StepOnePlus Real-Time PCR System) 
 
2.1.9 Additional materials 
 6 well-culture-plate (Costar 3506) 
 24 well-culture-plate (Costar 3527) 
 96 well-culture-plate clear (TRP® 92096) 
 96 well-culture-plate white (VWR/Nunc 13602) 
 Counting chamber (Digital Bio DHC-N01) 
 Methanol (Sigma-Aldrich 24229) 
 Migration polycarbonate membrane 8µm pores (NewoProbe PFB8 302814) 
 Plastic tubes (Sterillin® 128A) 
 Reaction tube (Eppendorfer®) 
 Syringe filter 0,2 µm pores (Corning 431229) 
 Tissue culture dish (Sarstedt 83.1802) 
 Tissue culture flask (Sarstedt 83.1812) 
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2.2 Methods 
 
2.2.1 Cells 
For the project human periodontal fibroblasts from extracted retained human 
third molars were used - fibroblasts of the gingiva (GF) and the periodontal 
ligament (PDLF). The GF cells were taken from gingival remains, the PDLF 
were scraped from the last third of the roots and put into tissue culture dishes. 
The cells were cultivated until the culture dish was covered. Then transferred to 
tissue culture flasks with SC-medium or stored in frozen nitrogen until further 
use. For the cells’ sustainment the medium was replaced every 2-3 days. The 
cell culture flasks were changed after four passages and stored in an incubator 
at 37°C, 95% humidity and 5% CO2. 
 
Splitting 
When the density of cells was high enough, the wall of the cell culture flask 
covered with nearly no free room in between the cells, they were harvested. 
The medium was aspirated, the cells washed with PBS and given TE to 
dispatch the cells from the tissue culture flask. SC-medium was added to stop 
the reaction and the cells mechanically flushed from the cell culture flask’s wall 
and put into a plastic tube. Then they were centrifuged, resuspended in new 
SC-medium and returned into the cell culture flasks in a lower concentration. 
With each splitting the cells aged one passage; the cells were used till passage 
eight. 
 
Harvesting 
For the experiments the cells were split and the number of cells determined with 
a counting chamber. The cell concentration was adjusted with the dilution 
factor. The used concentrations were 1.7 x 105 c/ml (equals 50,000 c/cm2) and 
1 x 106 c/ml (equals 300,000 c/cm2) depending on the experiment. 
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2.2.2 Alkaline phosphatase staining 
ALP is an enzyme produced by mature osteoblasts. In histochemical staining 
alkaline phosphatase is used as a differentiation marker to determine the 
differentiation activity of osteoblasts. The protocol used was taken from 
D’Ippolito et al. (84) In this protocol the staining caused a yellow coloring in 
precursor cells and blue staining in differentiating cells. 
 
Cells were platted on 96 well-culture-plates - 1.7 x 105 c/ml in SC-medium. After 
24 h the cells were stimulated with SF-medium in presence and absence of 
rhTGF-β1 (10 ng/ml), rhsclerostin (100 ng/ml), rhPTH (100 ng/ml) and α-hSOST 
(1:500), alone and in combination. After 72 h of incubation by 37°C, the cells 
were washed with PBS and affixed with neutral-buffered formalin. Subsequently 
washed with PBS, incubated with staining solution (pH 9), washed with a.d. 
Lastly the turnover rate of the substrate was photometrically measured at 550 
nm and photos taken. 
 
 
2.2.3 Viability assay, proliferation assay, protein synthesis assay 
Cells were platted on 96 well-culture-plates - 1.7 x 105 c/ml in SC-medium. After 
24 h the cells were stimulated in SF-medium with rhPDGF-BB (30ng/ml), PRS 
(1:5) and rhbFGF (10 ng/ml) alone and in combination with rhsclerostin 
(100ng/ml, 10 ng/ml, 1 ng/ml). After incubation for 24 h the analyses were done 
with corresponding assays. 
 
Viability assay 
MTT was added to the stimulated cells. After incubation for 2 h the MTT-media 
mix was removed, DMSO put into the wells and the plate tapped lightly until the 
formazan crystals dissolved. The OD was measured by 550 nm in the 
photometer. The assay analyses the impact of signaling molecules on cell 
viability, e.g. cytotoxicity. Yellow MTT substrate is reduced to violet formazan 
crystals by reducing enzymes, produced only in living cells. In a photometer, the 
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OD of the transformed substrate is measured and shows the effect of signaling 
molecules on the viability of cells in comparison to an unstimulated control. 
 
 
Proliferation assay 
To the stimulated cells 3[H]thymidine was added, incubated for 6 h, washed in 
PBS and dried overnight. Subsequently a scintillate cocktail was added, a 
sealing put on top and the plate put into the beta-counter. The assay analyses 
the impact of signaling molecules on cell proliferation. The added 3[H]thymidine 
is integrated into the DNA of proliferating cells. The incorporated 3[H]thymidine 
sends out scintillating light signals which are detected by the beta-counter. The 
counted signals per minute (cpm) correspond with the proliferation rate. This 
shows the effect of signaling molecules on the proliferation of cells, either 
inhibiting or increasing, compared to an unstimulated control. 
 
Protein synthesis assay 
To the stimulated cells 3[H]leucine was added, incubated for 6 h, washed in 
PBS and dried overnight. Next a scintillate cocktail was added, a sealing put on 
top and the plate put into the beta-counter. The assay analyses the impact of 
signaling molecules on cell protein synthesis rate. The added 3[H]leucine is 
integrated into produced proteins. The incorporated 3[H]leucine sends out 
scintillating light signals which are detected by the beta counter. The cpm 
correspond with the rate of protein synthesis. This shows the effect of signaling 
molecules on the protein synthesis rate of cells, either inhibiting or increasing, 
compared to an unstimulated control. 
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2.2.4 Boyden-Chamber-Assay 
The migration assay analyses the chemotactical effect of signaling molecules 
on cells. An agent is chemotactical when it induces cells to move in its direction. 
The Boyden-chamber (85) consists of two chamber parts, a lower and an upper, 
with a thin permeable membrane in-between, that catches migrating cells. 
 
The lower chamber was loaded with cells - 1 x 106 c/ml in SF-medium – a thin 
membrane put on it and the upper chamber added on top. The upper part was 
filled with different stimulations, PRS (1:5), Sclersotin (100 ng/ml), PTH (100 
ng/ml), in SF-medium - alone and in combination. After incubation for 3 h at 
37°C the membrane was washed and dried. Subsequently the cells were affixed 
with methanol, put into a red colour solution followed by a blue colour solution 
for staining, washed under water and dried. Cells that migrated through the 
membrane were stained violet; compared to an unstimulated control it showed if 
signalling molecules had a chemotactical impact. (Figure 22) 
 
 
Figure 22: Standard Boyden-Chamber-Assay. (86) 
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2.2.5 Western Blot 
The Western Blot, or protein immunoblot, is used for the search of specific 
proteins from samples. This is achieved through separation of proteins by size 
in gel electrophoresis, followed by transfer of the proteins onto a membrane and 
binding of antibodies to the wanted protein. 
 
Sample preparation 
Cells were seeded in 6-well culture plates – 1.7 x 105 c/ml in SC-medium - and 
left for 24 h to settle down. Subsequently the cells were stimulated in OD-
medium with signaling molecules for 24 h, except for one row of samples which 
were incubated for 3 h, 6 h, 24 h, 48 h and 72 h. After the incubation period 
medium was removed, cells washed with PBS and mixed with SDS-sample 
buffer. Following cells were scraped from the well bottom using a police rubber 
man, put into reaction tubes, sonicated, thermocycled at ~95°C, centrifuged, 
transferred to new tubes and stored at -20°C until further use. 
Signaling molecules used were - alone and in combination – rhPDGF-BB (30 
ng/ml), TGF-β1 (10 ng/ml, 1 ng/ml, 1 pg/ml, 10 pg/ml, 1 pg/ml), PTH (100ng/ml), 
rhBMP-6 (30 ng/ml), PRS (1:5) and L-Mimo (1 nM). The primary antibodies 
(1:1000) with their corresponding secondary antibody (1:2000) used were α-
hβActin with α-goat HRP and α-hSOST with α-goat HRP. 
 
Procedure 
A polyacrylamide gel was prepared, consisting of a separating gel and on top a 
stacking gel with slots for the samples. The samples were loaded, the gel plates 
put into the electrophoresis apparature, immersed in runnig buffer and run by 
200 V for 45 minutes. Depending on the concentration of the acrylamid gel 
proteins were divided by size; smaller proteins wandered faster and further 
through the gel than bigger ones. 
Next the segregated proteins were transferred from the polyacrylamide gel on a 
nitrocellulose membrane. Therefore a “sandwich” was built, sponge – filter 
paper – gel – membrane – filter paper – sponge. Put into the apparatus with 
transfer buffer and a cool aid for 45 minutes by 350 mA. Afterwards the 
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membrane was washed in TBS, incubated with blocking buffer (5% milk powder 
in TBS-T) for 1 h and again washed with TBS-T to remove excess blocking 
buffer. Then primary antibody (1:1000 in 5%BSA-TBS-T) specific to the target 
protein was added. After incubation over night by 4°C the membrane was 
washed in TBS-T, specific second antibody (1:2000 in 5% milk powder in TBS-
T) added for 1 h and washed again in TBS-T. The blocking buffer bound 
unspecific to protein binding sites and later the specific binding antibodies 
replaced the bound milk proteins on the antigens. Subsequently the membrane 
was covered with detection solution and put in a radioactive cassette. In the 
darkroom an x-ray film was put on the membrane and developed. 
Chemo-luminescence was used for detection. The detection solution bound to 
the HRP on the secondary antibodies and blackened the x-ray film in the places 
where the proteins were on the membrane. The size and intensity of the 
blackening site showed the quantitative amount of specific bound protein. 
(Figure 23) 
 
 
Figure 23: HRP Western Blot radioactive detection system. (87) 
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2.2.6  ELISA 
The method is used for detection of a specific protein; based on the 
accumulation of antibody-antigen-antibody-enzyme complexes. The specific 
protein’s antigens bind to the antibodies on the plate, the second enzyme-linked 
antibody binds on the protein. The substrate reacts with the linked enzyme and 
causes a color change. (Figure 24) 
 
 
Figure 24: Standard ELISA 
 
 
Sample preparation 
Cells were seeded in 24 well-culture-plates – 1.7 x 105 c/ml in SC-medium. 
After 24 h the cells were stimulated in OD-medium with TGF-β1 (10 ng/ml) for 
72 h. Afterwards the supernatant was transferred to reaction tubes. The cells 
were washed with PBS, which was replaced by Triton (0,2%), sonicated, 
centrifuged, put into new tubes and stored at -20°C until further use. 
 
Procedure 
Samples were put into cell plates, coated with antibodies specific for a protein. 
Then a second specific enzyme-linked antibody was added, which bound to the 
protein. After incubation for ~24 h the cell plates were washed, conjungate 
buffer added, incubated for 1 h, washed and substrate added. After 30 minutes 
the procedure was stopped and the OD measured at 450 nm and 630 nm for 
sclerostin. A standard curve was created and the protein concentrations 
estimated for sample data. 
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2.2.7  PCR 
In the PCR, a strand of mRNA is used as template, primers - with specific 
sequence - bind to the mRNA and build the complementary DNA sequence. 
Through an increase in temperature, the complementary strands dissolve. By 
lowering the temperature new primers can bind to the DNA strands and a new 
cycle is started. The constant repeat of cycles amplifies the specific DNA 
sequences exponentially and allows an assessment of the amount of mRNA 
contained in the original sample. (Figure 25) 
 
 
Figure 25: Standard PCR 
 
Sample and RNA preparation 
Cells were seeded in 6-well culture plates – 1.7 x 105 c/ml in SC-medium - and 
left for 24 h to settle down. Subsequently the cells were stimulated in OD-
medium with TGF-β1 (10 ng/ml) for 12 h and 24 h. After incubation, the cells 
were washed with PBS, which was replaced by lysis buffer containing beta-
mercaptoethanole (β-ME). Following cells were scraped from the well bottom 
using a police rubber man, put into reaction tubes, homogenized with sonicator 
and 70%-ethanol added. In the next step the RNA was purified with the 
RNAeasy kit in several washing and eluation steps following the protocol and in 
a.d. resuspended. The samples were stored at - 80°C until further use. 
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RNA quantification and DNase digestion 
For verification of RNA presence and quality the samples were loaded on an 
agarose gel in TAE-buffer and checked - via built in ß-ME – under UV light and 
photographed. For RNA quantification the samples’ OD was measured and the 
concentration calculated for 1 µg RNA per sample per experiment. Before the 
samples could be used for an experiment the DNase had to be digested, 
otherwise the DNases would degenerate the, during PCR generated, DNA. For 
the DNase digestion a DNase I-kit was used. The dilution of the RNA 
concentration of 1 µg and the DNase digestion were done separately for each 
experiment with the required amount of RNA needed for the experiment.  
 
Procedure 
Master Mix was made of buffer and enzyme from the SYBR® Green one step 
qRT-PCR Kit mixed with RNase-free/DNase-free/purified water, divided into 
separate reaction tubes and the respective primers added. Digested and diluted 
RNA was put into the wells of the PCR plates first then the MM according to the 
loading scheme was added and the plate and a seal put on top. Directly after 
the plate was put into the PCR machine. The standard program consisted of 40 
cycles and a followed melting curve. The analysis of the qRT-PCR was done 
with Microsoft® Excel 2007 and the 2-ΔΔCT method after Livak and Schmittgen. 
(88, 89) The stimulated samples were normalized to an external control gene, 
the house keeping gene β-actin. β-actin was chosen since it is expressed in 
different tissues and cells at a similar level. 
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3 Results 
 
3.1 Question 1 
Do signaling molecules have an effect on the expression of sclerostin in 
periodontal fibroblasts? 
 
3.1.1 Screening 
To answer objective 1, GF and PDLF were screened with different signaling 
molecules - PTH, TGF-β, BMP-6, PDGF-BB - and the effect on protein 
expression looked at via Western Blot. To ensure that α-hSOST binds sclerostin 
and not another of similar size a sample with rhsclerostin (30 ng/ml) was used 
for verification. 
 
 
 
Figure 26: Screening with signaling molecules – Western Blot. GF and PDLF showed an increase in 
expression of sclerostin by stimulation with TGF-β compared to the unstimulated control. For 
verification of sample functionality β-actin was used; rhsclerostin for the α-hSOST specifity. 
 
The Western Blot showed an increase in the expression of sclerostin by TGF-β 
and TGF-β + PTH in comparison to the unstimulated control. PTH alone, BMP-
6, and PDGF-BB displayed no difference to the control. The band for 
rhsclerostin was the same height as the other bands. This supported the 
conclusion that the bound protein was sclerostin and that TGF-β increased the 
expression of sclerostin. 
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3.1.2 Reproducibility 
To see if the TGF-β-induced effect was reproducible, GF and PDLF from 
different donors were incubated with TGF-β. The change in expression was 
observed on mRNA level with PCR and on protein level with Western Blot and 
ELISA. 
 
3.1.2.1 PCR 
 
 
Figure 27: Reproducibility – PCR. The expression of SOST-mRNA is in all three donors of GF and 
PDLF higher than the control (dotted line). The fold-change differs between the donors. 
 
In the PCR, all three TGF-β stimulated GF and PDLF donors showed an 
increase in the expression of SOST-mRNA compared to the control after 
normalization to β-actin. The increase of mRNA was 9.1-fold, 8.7-fold, 3.9-fold 
by the GF donors and 6-fold, 2.5-fold and 8-fold the PDLF donors. 
 
3.1.2.2 Western Blot 
 
Figure 28: Reproducibility – Western Blot. GF 1/2 and PDLF 1 showed an increase in expression of 
sclerostin by stimulation with TGF-β compared the respective unstimulated control. For 
verification of sample functionality β-actin was used. 
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In the Western Blot, TGF-β increased the expression of sclerostin compared to 
the unstimulated control, but the level of the expression differed between 
donors. GF 2 and PDL 1 showed strong signal - more sclerostin protein - while 
GF 1 had a lighter and PDL 2 barely any signal compared to the respective 
unstimulated controls. 
 
3.1.2.3 ELISA 
 
 
 
Figure 29: Reproducibility – ELISA. The expression of the protein sclerostin (in pmol/l) is shown for 
GF 1/2 and PDLF 1/2. All donors showed an increase by stimulation with TGF-β compared to 
respective unstimulated control – in lysat and supernatant. 
 
The ELISA data also shows higher amount of sclerostin in TGF-β stimulated 
samples in comparison to the respective controls – lysat and supernatant. 
Although all donors produce more protein with stimulation, the amount differs 
between the donors as well as between origin of the cells.  
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Next it was of interest what kind of conditions were necessary to achieve the 
increased expression of sclerostin. Therefore, it was tested for time-
dependency and dose-dependency.  
 
3.1.3 Time 
To see what time period was necessary for TGF-β to increase sclerostin, cells 
were incubated with TGF-β for different time points. 
 
 
Figure 30: Time – Western Blot. GF and PDLF showed an increase in expression of sclerostin by 
stimulation with TGF-β after 24 h compared to the respective unstimulated control. For verification 
of sample functionality β-actin was used. 
 
An increase of the expression of sclerostin was detected at 24 h on protein level 
via Western Blot in GF and PDLF. The Western Blot showed an increase of 
sclerostin between 24 h – 48 h in GF and 24 h – 72 h in PDLF. The increase 
was strongest after 24 h and decreased with continued time. Here, it took 24 h 
for TGF-β induced increase to take place. 
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3.1.4 Dose  
To see what concentration of TGF-β was necessary to increase sclerostin, cells 
were incubated with TGF-β in different concentrations (dilution row 1:10). 
 
 
Figure 31: Dose – Western Blot. An increase in expression of sclerostin by stimulation with TGF-β1 
-10 ng/ml, 1 ng/ml, 0.1
 
ng/ml - compared to unstimulated control was shown. For verification of 
sample functionality β-actin was used. 
 
The Western Blot showed that concentrations of TGF-β between 10 – 0.1 ng/ml 
increased the expression of sclerostin compared to the unstimulated control. 10 
ng/ml and 1 ng/ml showed the same strength and 0.1 ng/ml a slightly weaker 
signal intensity. 
 
3.1.5 Result 1 
TGF-β increased the expression of sclerostin on mRNA and protein level. The 
effect is donor-, time-, and dose-dependent. This gives rise to the question what 
effect sclerostin has on cell functions. 
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3.2 Question 2 
Does sclerostin effect cell functions through an autokrine mechanism? 
To answer question 2 the effect of sclerostin (100 ng/ml, 10 ng/ml, 1 ng/ml) 
alone and in combination - with PDGF-BB, PRS, bFGF, PTH - was tested on 
the cell functions viability, proliferation, protein synthesis, and chemotaxis. It 
was also tested for a possible impact of sclerostin on fibroblastic differentiation. 
 
3.2.1 Viability 
To test for possible effects of the growth factors on the viability of GF and PDLF 
a viability assay was used. 
 
Figure 32: Viability. None of the growth factors used – w/o, PDGF-BB, PRS, and bFGF – showed an 
effect on viability in GF and PDLF compared to the respective unstimulated control (dotted line). 
Neither alone nor in combination with different concentrations of sclerostin. 
 
Recombinant sclerostin alone showed no effect on the viability of GF and PDLF 
compared to control. Combination of sclerostin with PDGF-BB, PRS, and bFGF 
had no impact - in the used concentrations – compared to respective controls.  
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3.2.2 Proliferation 
To test for possible effects of the growth factors on the proliferation of GF and 
PDLF a proliferation assay was used. 
 
Figure 33: Proliferation. None of the growth factors used – w/o, PDGF-BB, PRS, and bFGF – 
showed an effect on proliferation in GF and PDLF compared to the respective unstimulated control 
(dotted line). Neither alone nor in combination with different concentrations of sclerostin. 
 
Recombinant sclerostin – 100 ng/ml, 10 ng/ml, 1 ng/ml - alone showed no effect 
on the proliferation of GF and PDLF compared to the control. The combination 
of sclerostin with PDGF-BB, PRS, and bFGF had no impact - in the used 
concentrations - compared to the respective controls. 
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3.2.3 Protein synthesis 
To test for possible effects of the growth factors on the protein synthesis rate of 
GF and PDLF a protein synthesis assay was used. 
 
Figure 34: Protein synthesis. None of the growth factors used – w/o, PDGF-BB, PRS, and bFGF – 
showed an effect on proliferation in GF and PDLF compared to the respective unstimulated control 
(dotted line). Neither alone nor in combination with different concentrations of sclerostin. 
 
Recombinant sclerostin – 100 ng/ml, 10 ng/ml, 1 ng/ml - alone showed no effect 
on the protein synthesis rate of GF and PDLF compared to the control. The 
combination of sclerostin with PDGF-BB, PRS, and bFGF had no impact - in the 
used concentrations - compared to the respective controls. 
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3.2.4 Chemotaxis 
To test for possible effects of the signaling molecules on the chemotaxis of GF 
and PDLF a Boyden-Chamber-assay was used. 
 
 
Figure 35: Boyden-Chamber-Assay. PRS and PDGF-BB – alone and in combination with sclerostin 
– induced cells to migrate. PTH, w/o, and sclerostin alone had no effect on cells. w/o verified that 
migratory had to be stimulant-dependent. 
 
The cells in the unstimulated control did not migrate, meaning possible 
migration had to be induced by the signaling molecules. PRS and PDGF-BB 
alone and combined with sclerostin induced the cells to migrate. Neither 
sclerostin alone nor PTH provoked migration of cells. These data suggest that 
sclerostin shows no chemotactical effect on GF and PDLF in the used 
concentration. 
 
.  
 - 58 - 
3.2.5 Differentiation of fibroblasts 
To determine, if signaling molecules have an effect on the differentiation of 
periodontal fibroblasts and therefore possible a regulatory effect on the 
expression of sclerostin, GF and PDLF were incubated with signaling molecules 
– sclerostin, TGF-β, PTH – and determined the differentiation activity via ALP 
staining. 
 
 
Figure 36: Differentiation - ALP staining. GF and PDLF are both positive for fibroblast 
differentiation GF stronger than PDLF. TGF-β showed an inhibitory effect, sclerostin and PTH no 
effect on the cells compared to the respective controls control. 
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GF and PDLF showed differentiation activity and were positive for blue staining, 
GF stronger than PDLF. GF 3 had the most intense staining followed by GF 1/2; 
PDLF 1/3 had the same amount of staining while PDFL 2 only showed single 
ALP positive cells. Sclerostin and PTH had no effect on the staining. TGF-β 
showed an inhibitory effect on differentiation in comparison to the respective 
unstimulated control. 
 
3.2.6 Mediator of inhibiting effect 
To see wether this inhibitory effect of TGF-β was mediated by sclerostin, 
mediated GF and PDLF were incubated with TGF-β and α-hSOST– alone and 
in combination – and tested for differentiation activity via photometry and ALP 
staining. 
 
3.2.6.1 Photometry 
 
Figure 37: Mediation - Photometry. Compared to the respective unstimulated control (dotted line) 
TGF-β alone and in combination with α-hSOST showed an inhibitory effect, α-hSOST none. The 
effect was observed in GF 1/2 and PDLF 2; PDLF 1 had no reaction at all. 
 
GF 1/2 as well as PDLF 2 showed a reaction to stimulation, only PDLF 1 had 
none. TGF-β and TGF-β + α-hSOST showed an inhibitory effect on ALP, α-
hSOST alone had no impact, compared to the respective controls.   
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3.2.6.2 ALP staining 
 
 
Figure 38: Mediation - ALP staining. GF and PDLF are both positive for fibroblast differentiation - 
GF stronger than PDLF. α-hSOST alone had no effect, TGF-β and TGF-β + α-hSOST showed 
reduced staining, compared to the respective controls. Therefore the observed inhibitory effect 
was TGF-β mediated. 
 
GF and PDLF showed differentiation activity and were positive for blue staining, 
GF stronger than PDLF. GF 1 had the most intense staining followed by GF 2; 
PDLF 2 had a light staining while PDLF 1 had none. Compared to control α-
hSOST alone had no effect. TGF-β and TGF-β + α-hSOST showed reduced 
staining compared to the respective controls. 
 
3.2.7 Result 2 
Recombinant sclerostin showed no effect on cell viability, proliferation, protein 
synthesis, and chemotaxis. Sclerostin had no effect on fibroblast differentiation 
– neither α-hSOST, recombinant protein nor sclerostin released in the presence 
of TGF-β. Therefore the observed inhibitory effect on differentiation was TGF-β 
mediated.  
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3.3 Summary 
 
 
Objective 1 
TGF-β increased the expression of sclerostin on mRNA and protein level. The 
effect is donor-, time-, and dose-dependent.  
 
Objective 2 
Sclerostin had no direct effect on cell viability, proliferation, protein synthesis, 
and chemotaxis. Fibroblast differentiation was not affected by sclerostin – 
neither α-hSOST, recombinant protein nor sclerostin released in the presence 
of TGF-β. Therefore the observed inhibitory effect was TGF-β mediated.  
 
 
Summary 
TGF-β1 increased the expression of sclerostin in periodontal fibroblasts. 
Sclerostin itself had no effect on cell functions. However, an autokrine/ 
parakrine mechanism cannot be ruled out. 
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4 Discussion 
 
 
Our main finding is that TGF-β1 up-regulates the expression of sclerostin in 
periodontal ligament fibroblasts and gingival fibroblasts. This observation is 
important since sclerostin, a key regulator of bone regeneration through 
inhibiting the Wnt-signaling pathway, is not exclusively expressed in osteocytes, 
but also in cells of the periodontium. (58, 78, 79) Sclerostin alone did not 
influence viability, proliferation, proteinsythesis, chemotaxis, and osteogenic 
differentiation; an autokrine function could not be shown. 
 
Regulation of sclerostin expression through TGF-β1 in GF and PDLF has not 
yet been reported, thus being a novel finding. The effect of TGF-β1 on the 
expression of sclerostin has only been looked at in one study by Sutherland et 
al. in osteoblasts. (90) However, compared to our study, the effect of TGF-β1 on 
the expression of sclerostin was deemed negligible. (90) A study in neonatal 
mice showed enhanced gene expression of TGF-β receptors type 2/3 and 
sclerostin in the perichondrium of the temporomandibular joint. The functional 
role of sclerostin was defined as unclear; a connection between an increase of 
TGF-β and sclerostin was not drawn. (91) Gao et al. showed that the TGF-β 
receptors type 2/3 are expressed in the periodontium. (92) Also regulatory 
effects of BMPs on the expression of sclerostin have been published. 
Expression of sclerostin is induced by BMP-2/4/6 in osteogenic cells of human 
and mouse. (90) The knock-out of BMP receptor in osteoblasts caused 
decrease in sclerostin and enhancement of BMP signalling increased sclerostin.  
(93, 94) All together a regulation of sclerostin through TGF-β1 is supported by 
earlier studies that showed the presence of TGF-β in the periodontium and a 
common increase in the expression of TGF-β and sclerostin. 
 
Our finding that sclerostin is expressed in periodontal cells was also observed in 
other studies. Cementocytes in the cementum (52, 78) PDLF in the PDL (78), 
osteoblasts and osteocytes in bone (36, 51-55, 58, 62, 90) as well as in 
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periodontal cells in mineralizing matrices (52, 90). Also recently odontoblasts 
have been shown to be able to express sclerostin. (79) That GF produce 
sclerostin like PDLF is supported by the fact that sclerostin is also expressed in 
other soft tissues in adults (36, 37, 49, 50) and TGF-β1 in gingival tissue (95). 
Further it was shown that GF and PDLF are similar to osteoblasts, with the 
potential to produce mineralizing structures like cementum or bone. (96) 
Summed up, the expression of sclerostin in GF and PDLF and the regulation by 
TGF-β1 is supported by the presence of TGF-β1 and/or sclerostin in PDL and 
gingiva. 
 
The literature contradicted our data that showed no effect of rhsclerostin on 
proliferation, viability, and osteoblastogenesis. A study showed a significant 
decrease in proliferation and osteoblastigenesis, as well as a significant 
increase in apoptosis. (55) An inhibition of osteblastic differentiation was also 
reported in hMSC. (53) The time-dependency of the expression of sclerostin – 0 
h no sclerostin, 24 h sclerostin – in OD-medium has also been observed in 
PDLF. (78) The use of the same antibody for Western Blot as in our study 
supports that the found protein was sclerostin. (78) Our data on sclerostin’s 
effect on cell functions differs from literature. Reasons therefore may be the use 
of different fibroblasts types and incubation times.  
 
Of clinical relevance is the interaction of TGF-β1 and sclerostin in dental defects 
and chronic inflammations. TGF-β is involved in wound healing (95); inhibition 
of sclerostin up-regulated healing in bone defects. (66). The study’s data 
support a regulatory interaction between these two factors. Treatment with 
sclerostin neutralizing antibodies could improve and speed up the healing at 
defect sites or in chronic inflammation, enhance the healing of implants into the 
alveolar bone as well as be used in osteoporotic patients to lower the risk of 
tooth loss. (81) 
 
Limiting factors of the study were, for example, that the effect of TGF-β1 on 
sclerostin expression was only investigated in GF and PDLF. Other cell types - 
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cementocytes, osteoblasts, and osteocytes - express sclerostin as well (36, 51-
55, 90) and therefore should also be tested. Bioassays to determine the 
consequences of increased sclerostin are missing. Experiments with 
supernatants without the presence of TGF-β1 are a possibility for further 
research. The data for the impact of sclerostin on osteoblastogenesis differ from 
literature. It may be that the number of receptors was insufficient or a factor 
responsible for the expression of the receptors was missing. Further studies are 
of interest to determine the reasons. Due to the donors’ anonymity, gender, 
age, health status, and life style - smoking, drinking, medications - were 
unknown. The data are general and not specific to gender, age, or health. 
Therefore, this background information may help to explain different reactions 
and results between donors. Another restriction of this study is the in vitro 
model. In this closed system only a limited number of cell types and 
signaling/transcription/differentiation factors are present that interact and react 
together. 
 
Future studies should include in vivo animal or human models to show possible 
effects of TGF-β1 induced sclerostin expression in the periodontium in an open 
system. Further, studies to decipher the mode of regulation for sclerostin and 
the signaling pathway between TGF-β1 and sclerostin are needed. 
 
Summarizing the findings suggest that in the periodontium the bone regulator 
sclerostin is produced, and up-regulated by TGF-β1, a periodontal expressed 
growth factor. Thus, a functional role of sclerostin in the periodontium is 
possible. However, wether sclerostin has a physiological or a pathological 
function in periodontal tissues is still unknown. 
 
  
 - 65 - 
5 List of Figures 
 
 
Figure 1: Permanent dentition set ................................................................ - 15 - 
Figure 2: Tooth in cross-section ................................................................... - 16 - 
Figure 3: Periodontium ................................................................................. - 18 - 
Figure 4: Cementum .................................................................................... - 19 - 
Figure 5: Gingiva .......................................................................................... - 20 - 
Figure 6: PDL ............................................................................................... - 21 - 
Figure 7: Alveolar bone ................................................................................ - 21 - 
Figure 8: Oral fibroblasts .............................................................................. - 22 - 
Figure 9: PDLF ............................................................................................. - 23 - 
Figure 10: Cementoblast and cementocyte .................................................. - 23 - 
Figure 11: Osteoblasts ................................................................................. - 24 - 
Figure 12: GF and PDLF in vitro .................................................................. - 24 - 
Figure 13: Periodontitis, repair and regeneration ......................................... - 25 - 
Figure 14: Clinical manifestations of sclerosteosis and Van Buchem ........... - 28 - 
Figure 15: Locus of the SOST gene ............................................................. - 29 - 
Figure 17: SOST mRNA expression in human tissues ................................. - 30 - 
Figure 16: Amino acid sequence of sclerostin .............................................. - 30 - 
Figure 18: Wnt-signaling pathway ................................................................ - 31 - 
Figure 19: SOST(-/-) mouse ........................................................................... - 33 - 
Figure 20: Expression of sclerostin by cementocytes .................................. - 34 - 
Figure 21: Expression of sclerostin by osteocytes ....................................... - 34 - 
Figure 22: Standard Boyden-Chamber-Assay.............................................. - 43 - 
Figure 23: HRP Western Blot radioactive detection system ......................... - 45 - 
Figure 24: Standard ELISA .......................................................................... - 46 - 
Figure 25: Standard PCR ............................................................................. - 47 - 
Figure 26: Screening with signaling molecules ............................................ - 49 - 
Figure 27: Reproducibility – PCR ................................................................. - 50 - 
Figure 28: Reproducibility – Western Blot .................................................... - 50 - 
Figure 29: Reproducibility – ELISA .............................................................. - 51 - 
 - 66 - 
Figure 30: Time ............................................................................................. - 52 - 
Figure 31: Dose ............................................................................................ - 53 - 
Figure 32: Viability ........................................................................................ - 54 - 
Figure 33: Proliferation ................................................................................. - 55 - 
Figure 34: Protein synthesis ......................................................................... - 56 - 
Figure 35: Boyden-Chamber-Assay ............................................................. - 57 - 
Figure 36: Differentiation .............................................................................. - 58 - 
Figure 37: Mediation - Photometry ............................................................... - 59 - 
Figure 38: Mediation - ALP staining .............................................................. - 60 - 
  
  
 - 67 - 
6 References 
 
6.1 Figures 
 
 
Figure 12, 24 - 38: created by Martina Gruber 
 
Figure 1: Reference (7) 
Figure 2: Reference (9) 
Figure 3: Reference (14) 
Figure 4: Reference (15) modified  
Figure 5: Reference (16) 
Figure 6: Reference (17) 
Figure 7: Reference (18) 
Figure 8: Reference (20) 
Figure 9: Reference (15) modified 
Figure 10: (A) Reference (21) 
 (B) Reference (22) 
Figure 11: Reference (24) 
Figure 13: Reference (17) 
Figure 14: (A) Reference (41) 
 (B+C) Reference (44) 
Figure 15: Reference (40) 
Figure 16: Reference (47) 
Figure 17: Reference (37) 
Figure 18: Reference (57) 
Figure 19: Reference (61) 
Figure 20: Reference (52) 
Figure 21: Reference (52) 
Figure 22: Reference (86) 
Figure 23: Reference (87) modified 
 - 68 - 
 
  
 - 69 - 
6.2 Literature 
 
 
1. Baumhoer D, Steinbrück I, Götz W. Histologie: Kurzlehrbuch zum 
Gegenstandskatalog. 2 ed: Urban & Fischer 2003. 
2. Lippert H. Lehrbuch Anatomie. 6 ed: Urban & Fischer 2003. 
3. Waldeyer A. Anatomie des Menschen. 17 ed. Fanghänel J, Pera F, 
Anderhuber F, Nitsch R, editors: de Gruyter 2003. 
4. Jockenhövel F, Merker R. Kurzlehrbuch Physiologie. 4 ed. Hick C, Hick A, 
editors: Urban & Fischer 2002. 
5. Klinke R, Silbernagel S. Lehrbuch der Physiologie. 4 ed: Thieme Stuttgart 
2003. 
6. Shaw WC, Rees G, Dawe M, Charles CR. The influence of dentofacial 
appearance on the social attractiveness of young adults. Am J Orthod 1985 
Jan;87(1):21-6. 
7. AbyssDesign. [updated 21.03.2009; cited 20.04.2011]; Available from: 
http://users.forthnet.gr/ath/abyss/dep1151.htm. 
8. Drake R, Vogl A, Mitchell A. Grey's Anatomie für Studenten. 1 ed: Urban & 
Fischer 2007. 
9. myDr. [updated 09.2009; cited 20.04.2011]; Available from: 
http://www.everybody.co.nz/page-b0721dc3-766c-48fc-89f4366d334a76f4 
.aspx. 
10. Müller H. Parodontologie - Checklisten der Zahnmedizin. 2 ed: Thieme 
Stuttgart 2006. 
11. Cho MI, Garant PR. Development and general structure of the 
periodontium. Periodontol 2000 2000 Oct;24:9-27. 
12. Nanci A, Bosshardt DD. Structure of periodontal tissues in health and 
disease. Periodontol 2000 2006;40:11-28. 
13. Junqueira LC, Carneiro J. Zytologie, Histologie und mikroskopische 
Anatomie des Menschen. 4 ed. Berlin: Springer 1996. 
 - 70 - 
14. Chen FM, Jin Y. Periodontal tissue engineering and regeneration: current 
approaches and expanding opportunities. Tissue Eng Part B Rev 2010 
Apr;16(2):219-55. 
15. Islam M. PDL. Oral Histology, School of Dental Sciences Universiti Sains;  
[cited 01.05.2011]; Available from: 
http://www.kck.usm.my/ppsg/histology/PDL_4.htm. 
16. Listgarten M. Gingiva. University of Pennsylvania and Temple University; 
1999 [updated 06.12.2009; cited 04.05.2011]; Available from: 
http://www.dental.pitt.edu/informatics/periohistology/de/gingiva_images/hist
o31a2.htm. 
17. Bosshardt DD, Sculean A. Does periodontal tissue regeneration really 
work? Periodontol 2000 2009;51:208-19. 
18. Islam M. Alveolar Bone. Oral Histology, School of Dental Sciences 
Universiti Sains; [cited 01.05.2011]; Available from:  
http://www.kck.usm.my/ppsg/histology/AB_2.htm. 
19. Berkovitz BK, Holland GR, Moxham BJ. Oral anatomy, histology and 
embryology. 4 ed: Elsevier Health Science 2009. 
20. Espinosa L, Sosnik A, Fontanilla MR. Development and preclinical 
evaluation of acellular collagen scaffolding and autologous artificial 
connective tissue in the regeneration of oral mucosa wounds. Tissue Eng 
Part A 2010 May;16(5):1667-79. 
21. Listgarten M. Cementoblast. University of Pennsylvania and Temple 
University 1999 [updated 06.12.2009; cited 01.05.2011]; Available from: 
http://www.dental.pitt.edu/informatics/periohistology/en/cementum/histo115
a2.htm. 
22. Listgarten M. Cementocyte. University of Pennsylvania and Temple 
University; 1999 [updated 06.12.2009; cited 01.05.2011]; Available from: 
http://www.dental.pitt.edu/informatics/periohistology/en/cementum/histo116
a2.htm. 
23. Pietschmann P, Diel IJ, Fahrleitner-Pammer A, Griesmacher A, Gruber R, 
Obermayer-Pietsch B, et al. Osteoimmunologie - Zytokine und Biologika in 
der Osteologie. 1 ed: Uni-Med Verlag Bremen 2008. 
 - 71 - 
24. Listgarten M. Osteoblasts. University of Pennsylvania and Temple 
University; 1999 [updated 06.12.2009; cited 01.05.2011]; Available from: 
http://www.dental.pitt.edu/informatics/periohistology/en/PDL_images/histo8
5a2.htm. 
25. Lackler KP, Cochran DL, Hoang AM, Takacs V, Oates TW. Development of 
an in vitro wound healing model for periodontal cells. J Periodontol 2000 
Feb;71(2):226-37. 
26. Gängler P, Hoffmann T, Willershausen B, Schnwenzer N, Ehrenfeld M. 
Zahn-Mund-Kiefer-Heilkunde. Lehrbuchreihe zur Aus- und Weiterbildung: 
Konservierende Zahnheilkunde und Parodontologie. 3 ed: Thieme Stuttgart 
2005. 
27. RefSeq.   [cited 07.05.2011]; Available from: 
http://www.ncbi.nlm.nih.gov/nuccore/NG_012111.1. 
28. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth 
factor and its involvement in disease. Mayo Clin Proc 2006 Sep;81(9):1241-
57. 
29. Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant 
human platelet-derived growth factor: biology and clinical applications. J 
Bone Joint Surg Am 2008 Feb;90 Suppl 1:48-54. 
30. Raja S, Byakod G, Pudakalkatti P. Growth factors in periodontal 
regeneration. Int J Dent Hyg 2009 May;7(2):82-9. 
31. Gene.   [cited 07.05.2011]; Available from: 
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&
TermToSearch=7040. 
32. Fujii S, Maeda H, Tomokiyo A, Monnouchi S, Hori K, Wada N, et al. Effects 
of TGF-beta1 on the proliferation and differentiation of human periodontal 
ligament cells and a human periodontal ligament stem/progenitor cell line. 
Cell Tissue Res 2010 Nov;342(2):233-42. 
33. Wen W, Chau E, Jackson-Boeters L, Elliott C, Daley TD, Hamilton DW. 
TGF-ss1 and FAK regulate periostin expression in PDL fibroblasts. J Dent 
Res 2010 Dec;89(12):1439-43. 
 - 72 - 
34. Oka S, Oka K, Xu X, Sasaki T, Bringas P, Jr., Chai Y. Cell autonomous 
requirement for TGF-beta signaling during odontoblast differentiation and 
dentin matrix formation. Mech Dev 2007 Jul;124(6):409-15. 
35. Oikawa T, Nomura Y, Arai C, Noda K, Hanada N, Nakamura Y. Mechanism 
of active eruption of molars in adolescent rats. Eur J Orthod 2010 Jul 22. 
36. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. 
Increased bone density in sclerosteosis is due to the deficiency of a novel 
secreted protein (SOST). Hum Mol Genet 2001 Mar 1;10(5):537-43. 
37. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll 
S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene 
product, a novel cystine knot-containing protein. Am J Hum Genet 2001 
Mar;68(3):577-89. 
38. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. 
Identification of a 52 kb deletion downstream of the SOST gene in patients 
with van Buchem disease. J Med Genet 2002 Feb;39(2):91-7. 
39. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, et al. 
Genomic deletion of a long-range bone enhancer misregulates sclerostin in 
Van Buchem disease. Genome Res 2005 Jul;15(7):928-35. 
40. Genetic Home Reference. [updated 06.2009; cited 07.05.2011]; Available 
from: http://ghr.nlm.nih.gov/gene/SOST. 
41. Beighton P. Sclerosteosis. J Med Genet 1988 Mar;25(3):200-3. 
42. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. 
Clin Genet 2003 Mar;63(3):192-7. 
43. Hofmeyr LM, Hamersma H. Sclerosing bone dysplasias: neurologic 
assessment and management. Curr Opin Otolaryngol Head Neck Surg 
2004 Oct;12(5):393-7. 
44. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lowik CW, 
Hamersma H, et al. Bone mineral density in sclerosteosis; affected 
individuals and gene carriers. J Clin Endocrinol Metab 2005 
Dec;90(12):6392-5. 
45. Stephen LX, Hamersma H, Gardner J, Beighton P. Dental and oral 
manifestations of sclerosteosis. Int Dent J 2001 Aug;51(4):287-90. 
 - 73 - 
46. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, et 
al. Characterization of the structural features and interactions of sclerostin: 
molecular insight into a key regulator of Wnt-mediated bone formation. J 
Biol Chem 2009 Apr 17;284(16):10890-900. 
47. Protein. [cited 01.05.2011]; Available from: 
http://www.ncbi.nlm.nih.gov/protein/AAK13454.1. 
48. Collette NM, Genetos DC, Murugesh D, Harland RM, Loots GG. Genetic 
evidence that SOST inhibits WNT signaling in the limb. Dev Biol 2010 Jun 
15;342(2):169-79. 
49. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, et al. 
Sclerostin is a novel secreted osteoclast-derived bone morphogenetic 
protein antagonist with unique ligand specificity. J Biol Chem 2003 Jun 
27;278(26):24113-7. 
50. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: 
current knowledge and future perspectives. Calcif Tissue Int 2010 
Aug;87(2):99-107. 
51. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, 
Lowik CW, et al. Sclerostin is a delayed secreted product of osteocytes that 
inhibits bone formation. FASEB J 2005 Nov;19(13):1842-4. 
52. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der 
Wee-Pals L, Balemans W, et al. Sclerostin in mineralized matrices and van 
Buchem disease. J Dent Res 2009 Jun;88(6):569-74. 
53. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, 
Karperien M, et al. Sclerostin is an osteocyte-expressed negative regulator 
of bone formation, but not a classical BMP antagonist. J Exp Med 2004 Mar 
15;199(6):805-14. 
54. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et 
al. Osteocyte control of bone formation via sclerostin, a novel BMP 
antagonist. EMBO J 2003 Dec 1;22(23):6267-76. 
55. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, 
et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel 
regulation of bone formation. Bone 2004 Oct;35(4):828-35. 
 - 74 - 
56. Galli C, Passeri G, Macaluso GM. Osteocytes and WNT: the mechanical 
control of bone formation. J Dent Res 2010 Apr;89(4):331-43. 
57. Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone 
Miner Metab 2009;27(3):265-71. 
58. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL. 
Osteocyte-derived sclerostin inhibits bone formation: its role in bone 
morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 2008 
Feb;90 Suppl 1:31-5. 
59. Choi HY, Dieckmann M, Herz J, Niemeier A. Lrp4, a novel receptor for 
Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone 
growth and turnover in vivo. PLoS One 2009;4(11):e7930. 
60. Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, et 
al. The binding between sclerostin and LRP5 is altered by DKK1 and by 
high-bone mass LRP5 mutations. Calcif Tissue Int 2008 Jun;82(6):445-53. 
61. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. 
Targeted deletion of the sclerostin gene in mice results in increased bone 
formation and bone strength. J Bone Miner Res 2008 Jun;23(6):860-9. 
62. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. 
SOST/sclerostin, an osteocyte-derived negative regulator of bone 
formation. Cytokine Growth Factor Rev 2005 Jun;16(3):319-27. 
63. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates 
bone response to mechanical unloading through antagonizing Wnt/beta-
catenin signaling. J Bone Miner Res 2009 Oct;24(10):1651-61. 
64. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic 
target for bone diseases. Expert Opin Ther Targets 2009 Apr;13(4):485-96. 
65. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome 
leads to bone-building antibodies. J Bone Miner Res 2010 Sep;25(9):1897-
904. 
66. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody 
treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 
2010 Nov;25(11):2412-8. 
 - 75 - 
67. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, et al. 
Inhibition of sclerostin by monoclonal antibody increases bone formation, 
bone mass, and bone strength in aged male rats. J Bone Miner Res 2010 
Dec;25(12):2647-56. 
68. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, et al. Inhibition of 
sclerostin by monoclonal antibody enhances bone healing and improves 
bone density and strength of nonfractured bones. J Bone Miner Res 2011 
May;26(5):1012-21. 
69. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al. 
Two doses of sclerostin antibody in cynomolgus monkeys increases bone 
formation, bone mineral density, and bone strength. J Bone Miner Res 2010 
May;25(5):948-59. 
70. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-
controlled, randomized study of AMG 785, a sclerostin monoclonal 
antibody. J Bone Miner Res 2011 Jan;26(1):19-26. 
71. Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis. 
Ann Rheum Dis 2011 Mar;70 Suppl 1:i119-22. 
72. van Oers RF, van Rietbergen B, Ito K, Hilbers PA, Huiskes R. A sclerostin-
based theory for strain-induced bone formation. Biomech Model 
Mechanobiol 2010 Nov 11. 
73. Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, 
Fyhrie DP, et al. Hypoxia decreases sclerostin expression and increases 
Wnt signaling in osteoblasts. J Cell Biochem 2010 May 15;110(2):457-67. 
74. Bellido T. Downregulation of SOST/sclerostin by PTH: a novel mechanism 
of hormonal control of bone formation mediated by osteocytes. J 
Musculoskelet Neuronal Interact 2006 Oct-Dec;6(4):358-9. 
75. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, et al. Chronic 
elevation of parathyroid hormone in mice reduces expression of sclerostin 
by osteocytes: a novel mechanism for hormonal control of 
osteoblastogenesis. Endocrinology 2005 Nov;146(11):4577-83. 
76. Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, et 
al. Calcitonin impairs the anabolic effect of PTH in young rats and 
 - 76 - 
stimulates expression of sclerostin by osteocytes. Bone 2010 
Jun;46(6):1486-97. 
77. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005 
Aug;37(2):148-58. 
78. Jager A, Gotz W, Lossdorfer S, Rath-Deschner B. Localization of 
SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal 
ligament cells in vitro. J Periodontal Res 2010 Apr;45(2):246-54. 
79. Naka T, Yokose S. Spatiotemporal expression of sclerostin in odontoblasts 
during embryonic mouse tooth morphogenesis. J Endod 2011 
Mar;37(3):340-5. 
80. Rooker SM, Liu B, Helms JA. Role of Wnt signaling in the biology of the 
periodontium. Dev Dyn 2010 Jan;239(1):140-7. 
81. Tezal M, Wactawski-Wende J, Grossi SG, Dmochowski J, Genco RJ. 
Periodontal disease and the incidence of tooth loss in postmenopausal 
women. J Periodontol 2005 Jul;76(7):1123-8. 
82. Gruber R, Karreth F, Fischer MB, Watzek G. Platelet-released supernatants 
stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-
dependent mechanism. Bone 2002 May;30(5):726-32. 
83. Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L. Hepatocyte 
growth factor/c-Met signaling promotes the progression of experimental 
human neuroblastomas. Cancer Res 2004 Sep 1;64(17):6109-18. 
84. D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Age-related 
osteogenic potential of mesenchymal stromal stem cells from human 
vertebral bone marrow. J Bone Miner Res 1999 Jul;14(7):1115-22. 
85. Neuro Probe Inc. [cited 06.04.2011]; Available from: 
http://neuroprobe.com/products/boyden.html. 
86. Kohidai L. Method for determination of chemoattraction in Tetrahymena 
pyriformis. Curr Microbiol 1995 Apr;30(4):251-3. 
87. Cell Signaling Technology, Inc. [cited 06.04.2011]; Available from: 
http://www.cellsignal.com/products/images/wb.jpg. 
 - 77 - 
88. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
2001 Dec;25(4):402-8. 
89. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative 
C(T) method. Nat Protoc 2008;3(6):1101-8. 
90. Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA. Unique 
regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones 
in human osteoblasts. Bone 2004 Aug;35(2):448-54. 
91. Hinton RJ, Serrano M, So S. Differential gene expression in the 
perichondrium and cartilage of the neonatal mouse temporomandibular 
joint. Orthod Craniofac Res 2009 Aug;12(3):168-77. 
92. Gao J, Symons AL, Bartold PM. Expression of transforming growth factor-
beta receptors types II and III within various cells in the rat periodontium. J 
Periodontal Res 1999 Feb;34(2):113-22. 
93. Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, 
et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP 
signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone 
Miner Res 2010 Feb;25(2):200-10. 
94. Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, et 
al. BMP signaling negatively regulates bone mass through sclerostin by 
inhibiting the canonical Wnt pathway. Development 2008 
Nov;135(22):3801-11. 
95. Ohshima M, Yamaguchi Y, Matsumoto N, Micke P, Takenouchi Y, Nishida 
T, et al. TGF-beta signaling in gingival fibroblast-epithelial interaction. J 
Dent Res 2010 Nov;89(11):1315-21. 
96. Lallier TE, Spencer A, Fowler MM. Transcript profiling of periodontal 
fibroblasts and osteoblasts. J Periodontol 2005 Jul;76(7):1044-55. 
 
 
